Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yves Mary

Showing results (91-100 of 101) with videos related to

Pageof 11
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2014
Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related deathPhilippe Moreau, Michele Cavo, Pieter Sonneveld, et al.
Leukemia|May 23, 2018
A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trialCharles Dumontet, Cyrille Hulin, Meletios A Dimopoulos, et al.
Leukemia|August 21, 2019
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trialThierry Facon, Meletios A Dimopoulos, Nathalie Meuleman, et al.
American Journal of Hematology|December 23, 2015
Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment studyMichael Loschi, Raphael Porcher, Fiorenza Barraco, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 11, 2020
Evolution of Endoscopic Lesions in Steroid-Refractory Acute Severe Ulcerative Colitis Responding to Infliximab or CyclosporineDavid Laharie, Arnaud Bourreille, Julien Branche, et al.
Lancet (London, England)|October 16, 2012
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trialDavid Laharie, Arnaud Bourreille, Julien Branche, et al.
Gastroenterology|September 22, 2014
Development of the Lémann index to assess digestive tract damage in patients with Crohn's diseaseBenjamin Pariente, Jean-Yves Mary, Silvio Danese, et al.
Inflammatory Bowel Diseases|May 12, 2011
Development of the Crohn's disease digestive damage score, the Lémann scoreBenjamin Pariente, Jacques Cosnes, Silvio Danese, et al.
Blood|September 22, 2005
Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapyThierry Facon, Jean-Yves Mary, Brigitte Pégourie, et al.
Blood Cancer Journal|October 24, 2025
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experiencePhilippe Moreau, Cyrille Hulin, Alexis Talbot, et al.
Pageof 11

Showing results (91-100 of 101) with videos related to

Sort By:
Pageof 11
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2014
Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related deathPhilippe Moreau, Michele Cavo, Pieter Sonneveld, et al.
Leukemia|May 23, 2018
A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trialCharles Dumontet, Cyrille Hulin, Meletios A Dimopoulos, et al.
Leukemia|August 21, 2019
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trialThierry Facon, Meletios A Dimopoulos, Nathalie Meuleman, et al.
American Journal of Hematology|December 23, 2015
Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment studyMichael Loschi, Raphael Porcher, Fiorenza Barraco, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 11, 2020
Evolution of Endoscopic Lesions in Steroid-Refractory Acute Severe Ulcerative Colitis Responding to Infliximab or CyclosporineDavid Laharie, Arnaud Bourreille, Julien Branche, et al.
Lancet (London, England)|October 16, 2012
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trialDavid Laharie, Arnaud Bourreille, Julien Branche, et al.
Gastroenterology|September 22, 2014
Development of the Lémann index to assess digestive tract damage in patients with Crohn's diseaseBenjamin Pariente, Jean-Yves Mary, Silvio Danese, et al.
Inflammatory Bowel Diseases|May 12, 2011
Development of the Crohn's disease digestive damage score, the Lémann scoreBenjamin Pariente, Jacques Cosnes, Silvio Danese, et al.
Blood|September 22, 2005
Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapyThierry Facon, Jean-Yves Mary, Brigitte Pégourie, et al.
Blood Cancer Journal|October 24, 2025
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experiencePhilippe Moreau, Cyrille Hulin, Alexis Talbot, et al.
Pageof 11